Clinical Trial Update: Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dalpiciclib as adjuvant therapy for HR-positive/HER2-negative early breast cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Early Breast Cancer, Adjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING